Neurogene Statistics
Total Valuation
Neurogene has a market cap or net worth of $334.07 million. The enterprise value is $76.20 million.
Important Dates
The next estimated earnings date is Friday, May 8, 2026, before market open.
| Earnings Date | May 8, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Neurogene has 15.57 million shares outstanding. The number of shares has increased by 21.40% in one year.
| Current Share Class | 15.57M |
| Shares Outstanding | 15.57M |
| Shares Change (YoY) | +21.40% |
| Shares Change (QoQ) | +4.32% |
| Owned by Insiders (%) | 10.15% |
| Owned by Institutions (%) | 56.36% |
| Float | 5.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.22 |
| P/TBV Ratio | 1.27 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.56, with a Debt / Equity ratio of 0.04.
| Current Ratio | 16.56 |
| Quick Ratio | 16.42 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -20,641.60 |
Financial Efficiency
Return on equity (ROE) is -31.41% and return on invested capital (ROIC) is -21.59%.
| Return on Equity (ROE) | -31.41% |
| Return on Assets (ROA) | -20.66% |
| Return on Invested Capital (ROIC) | -21.59% |
| Return on Capital Employed (ROCE) | -37.92% |
| Weighted Average Cost of Capital (WACC) | 14.25% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$689,702 |
| Employee Count | 131 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +173.55% in the last 52 weeks. The beta is 1.89, so Neurogene's price volatility has been higher than the market average.
| Beta (5Y) | 1.89 |
| 52-Week Price Change | +173.55% |
| 50-Day Moving Average | 19.87 |
| 200-Day Moving Average | 21.32 |
| Relative Strength Index (RSI) | 54.08 |
| Average Volume (20 Days) | 139,207 |
Short Selling Information
The latest short interest is 3.89 million, so 24.95% of the outstanding shares have been sold short.
| Short Interest | 3.89M |
| Short Previous Month | 3.67M |
| Short % of Shares Out | 24.95% |
| Short % of Float | 76.03% |
| Short Ratio (days to cover) | 18.95 |
Income Statement
| Revenue | n/a |
| Gross Profit | -74.89M |
| Operating Income | -103.21M |
| Pretax Income | -90.35M |
| Net Income | -90.35M |
| EBITDA | -100.12M |
| EBIT | -103.21M |
| Earnings Per Share (EPS) | -$4.24 |
Full Income StatementBalance Sheet
The company has $269.01 million in cash and $9.89 million in debt, with a net cash position of $259.12 million or $16.64 per share.
| Cash & Cash Equivalents | 269.01M |
| Total Debt | 9.89M |
| Net Cash | 259.12M |
| Net Cash Per Share | $16.64 |
| Equity (Book Value) | 264.89M |
| Book Value Per Share | 17.10 |
| Working Capital | 255.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$77.17 million and capital expenditures -$1.18 million, giving a free cash flow of -$78.36 million.
| Operating Cash Flow | -77.17M |
| Capital Expenditures | -1.18M |
| Depreciation & Amortization | 3.09M |
| Net Borrowing | -61,000 |
| Free Cash Flow | -78.36M |
| FCF Per Share | -$5.03 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Neurogene does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.40% |
| Shareholder Yield | -21.40% |
| Earnings Yield | -26.94% |
| FCF Yield | -23.37% |
Analyst Forecast
The average price target for Neurogene is $57.63, which is 168.67% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $57.63 |
| Price Target Difference | 168.67% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
